CC-91633

CC-91633 (also known as BMS-986397) is an orally bioavailable, first-in-class molecular glue degrader targeting casein kinase 1 alpha (CK1α). It belongs to the class of cereblon E3 ligase modulators (CELMoDs) and is designed to induce the degradation of CK1α via cereblon-mediated ubiquitination. This mechanism leads to activation of p53-dependent pathways, including upregulation of p21, PUMA, and BAX proteins, resulting in cell cycle arrest and apoptosis in malignant cells. The drug is being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS), particularly in patients with functional TP53. Currently, it is undergoing Phase 1 clinical trials for these indications[2][3][5][6][7].

Other names

CK1 alpha degrader CC-91633CK-1 alpha degrader CC-91633CK 1 alpha degrader CC-91633BMS-986397BMS986397BMS 986397